Rein Therapeutics Files 8-K
Ticker: RNTX · Form: 8-K · Filed: Sep 22, 2025 · CIK: 1420565
| Field | Detail |
|---|---|
| Company | Rein Therapeutics, Inc. (RNTX) |
| Form Type | 8-K |
| Filed Date | Sep 22, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-event, filing
TL;DR
Rein Therapeutics filed an 8-K on 9/22 for an event on 9/16. Details TBD.
AI Summary
Rein Therapeutics, Inc. filed an 8-K on September 22, 2025, reporting an event on September 16, 2025. The filing indicates a change in the company's status or operations, though specific details are not provided in this excerpt. The company was formerly known as Aileron Therapeutics, Inc.
Why It Matters
This filing signals a material event for Rein Therapeutics, Inc., requiring disclosure to investors and the public. The nature of the event could impact the company's stock and future prospects.
Risk Assessment
Risk Level: medium — The filing of an 8-K often indicates significant corporate events that could carry inherent risks for investors, but the specific nature of the event is not detailed here.
Key Numbers
- 001-38130 — SEC File Number (Identifies the company's filing with the SEC.)
- 13-4196017 — EIN (Employer Identification Number for tax purposes.)
Key Players & Entities
- Rein Therapeutics, Inc. (company) — Registrant
- Aileron Therapeutics, Inc. (company) — Former company name
- September 16, 2025 (date) — Earliest event date
- September 22, 2025 (date) — Filing date
FAQ
What specific event occurred on September 16, 2025, that necessitated this 8-K filing?
The provided excerpt does not specify the exact event that occurred on September 16, 2025. It only states that the 8-K is a 'Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934' and lists 'Other Events' as the item information.
When was Rein Therapeutics, Inc. formerly known as Aileron Therapeutics, Inc.?
The filing indicates that the date of the name change from Aileron Therapeutics, Inc. to Rein Therapeutics, Inc. was March 29, 2024.
What is Rein Therapeutics, Inc.'s principal executive office address?
Rein Therapeutics, Inc.'s principal executive offices are located at 12407 N. Mopac Expy., Suite 250, #390, Austin, Texas 78758.
What is the SIC code for Rein Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Rein Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What is the registrant's telephone number?
The registrant's telephone number, including area code, is (737) 802-1989.
Filing Stats: 1,215 words · 5 min read · ~4 pages · Grade level 16.8 · Accepted 2025-09-22 08:00:14
Filing Documents
- d902312d8k.htm (8-K) — 29KB
- 0001193125-25-210050.txt ( ) — 146KB
- rntx-20250916.xsd (EX-101.SCH) — 3KB
- rntx-20250916_lab.xml (EX-101.LAB) — 18KB
- rntx-20250916_pre.xml (EX-101.PRE) — 11KB
- d902312d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REIN THERAPEUTICS, INC. Dated: September 22, 2025 /s/ Brian Windsor Brian Windsor, Ph.D., Chief Executive Officer